

Autism treatment challenges: need for accelerated Research in Pharmacological Interventions

Bhuvanesh Sukhlal Kalal^{1,2*}, Vinitha Ramanath Pai¹ and Sham S Bhat³

¹Department of Biochemistry, Yenepoya Medical College, Yenepoya University, Mangaluru - 575018, India

²Yenepoya Research Centre, Yenepoya University, Mangaluru -575 018, India

³Department of Paedodontics, Yenepoya Dental College, Yenepoya University, Mangaluru -575018, India

***Corresponding Author:** Bhuvanesh Sukhlal Kalal, Department of Biochemistry, Yenepoya Medical College, Yenepoya University, Mangaluru-575018, Karnataka, India; and Yenepoya Research Centre, Yenepoya University, Mangaluru-575018, Karnataka, India.

Received: November 29, 2016; **Published:** December 06, 2016

Volume 1 Issue 1 December 2016

© All Copy rights are reserved by Bhuvanesh Sukhlal Kalal, *et al.*

Autism spectrum disorders (ASD) are a group of developmental disorders characterized by severe abnormalities in communications, social awareness and skills, along with presence of restrictive activities [1]. In addition, there is evidence of involvement of various genetic and environmental factors. There is a growing awareness of the condition, diagnostic substitution and emerging research explains the rise in incidence of ASD. Despite existence of best practice guidelines for ASD diagnosis, which are recognised internationally [2], there is inconsistency in the reporting by the professionals [3]. However, experts believe that the actual rate of incidence could be higher, and only limited number of cases are identified by available definitive diagnosis [4,5]. Further, heterogeneity of ASD poses significant challenge in identifying specific biomarkers [1].

In ASD, medications often target problems such as irritability, aggression, self-injury, hyperactivity, and inattention, rather than the core symptoms of the disorder [6,7]. Core symptoms can be defined as withdrawal from the social domain and typical restricted/repetitive symptoms in the behavior domain [6]. Though, several studies on treatment of ASD have been evaluated, there are considerable variables in the results reported leading to the lack of consistent findings [8]. These variables are seen in certain aspects of research methodology used (such as lack of control, heterogeneous samples, and imprecise measurement), type of clinical practice, and differences in social settings of the studies [9]. Moreover, the efficacy and tolerability of these medications in children with ASD is less favorable than data available in typically developing children with similar symptoms [7,8].

It is acknowledged that there are studies which describe the research in different aspects of therapeutic findings. However, lack of a valid and reliable clinical trial can be a big hindrance to translation of the research for autism. Medications which are not effective should probably be abandoned as potential treatments and those that are effective possibly should be considered for more research [6]. Escalating research in pharmacological interventions and understanding of pathogenic pathways can help in development of new and novel medications for treatment of core symptoms in ASD.

Financial support and sponsorship: Nil.

Conflict of interest: There are no conflicts of interest.

Citation: Bhuvanesh Sukhlal Kalal, *et al.* "Autism treatment challenges: need for accelerated Research in Pharmacological Interventions". *Clinical Biotechnology and Microbiology* 1.1 (2016): 9-10.

References

1. Kalal BS, *et al.* "Role of the immune system in the biology of autism spectrum disorders". *International Journal of Pharma and Bio Sciences* 7.3 (2016): 853-859.
2. Filipek PA, *et al.* "The screening and diagnosis of autism spectrum disorders". *Journal of Autism and Developmental Disorders* 29.6 (1999): 439-484.
3. Taylor LJ, *et al.* "Diagnostic evaluation for autism spectrum disorder: a survey of health professionals in Australia". *BMJ Open* 6.9 (2016):
4. Neggers YH. "Increasing prevalence, changes in diagnostic criteria, and nutritional risk factors for autism spectrum disorders". *ISRN Nutrition* 13. (2014): 514026.
5. Ziats MN and Rennert OM. "The Evolving Diagnostic and Genetic Landscapes of Autism Spectrum Disorder". *Frontiers in Genetics* 7.65 (2016):
6. Farmer C., *et al.* "Pharmacotherapy for the core symptoms in autistic disorder: current status of the research". *Drugs* 73.4 (2013): 303-314.
7. McClellan L., *et al.* "Evidence-Based Pharmacotherapy for Autism Spectrum Disorders". *Current Treatment Options in Psychiatry* 3.2 (2016): 161-181.
8. Doyle CA and McDougle CJ. "Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan". *Dialogues Clin Neurosci* 14.3 (2012): 263-279.
9. Frazier TW, *et al.* "Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder". *J Child Adolesc Psychopharmacol* 21.6 (2011): 571-579.